Join Baker Tilly for a mid-year check-in on the life sciences industry with our leaders, where we will reflect on key developments from the first half of the year and assess the trends shaping the remainder of 2025 and beyond, such as:
- Capital markets: The state of funding for emerging companies and the realities of scaling in a competitive environment
- Regulatory outlook: Updates on drug pricing transparency, gross-to-net dynamics and policy shifts tied to election-year agendas
- HCP engagement: Why simplification, standardization and compliance are more critical than ever
- Technology and risk: Leveraging tech to manage regulatory exposure and streamline operations
- Evidence generation: Demonstrating value throughout the product lifecycle to align with payer expectations
- Strategic response: Turning risk into opportunity amid rapid industry change
This mid-year session is designed to equip life sciences leaders with timely insights, actionable takeaways and the strategic foresight needed to adapt and thrive in a highly dynamic environment.
